Shields has been vocal about women's wellness and now backs an initiative for women to be aware of an infection that's ...

Topline results were announced from a phase 3 study assessing the immune response following coadministration of Arexvy and Shingrix.

Bank of America Securities analyst Graham Parry maintained a Sell rating on GlaxoSmithKline (GSK – Research Report) yesterday and set a ...

This Comment is linked to The Lancet Haematology Series on Sexual Health in Patients with Haematological Malignancies; we ...

GSK plc GSK announced positive topline results from a phase III study evaluating the co-administration of its two marketed ...

Below, check out the roundup of California Healthline’s coverage. For today's national health news, read KFF Health News’ Morning Briefing.

GSK has revised its annual vaccine sales forecast following new guidance on RSV from the CDC. But new evidence offers new ...

If approved, the co-administration of Arexvy and Shingrix could provide a more convenient vaccination regimen for patients ...

Reuters.com is your online source for the latest news stories and current events, ensuring our readers up to date with any ...

GSK (GSK) reached the main goal in a Phase 3 trial for its RSV shot, Arexvy co--administered with Shingles vaccine Shingrix.

In the study, co-administration of GSK's RSV vaccine Arexvy and shingles shot Shingrix elicited non-inferior immune responses ...

In a report released today, Peter Welford from Jefferies maintained a Buy rating on GlaxoSmithKline (GSK – Research Report), with a price ...